Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
about
Oncogenes: The Passport for Viral Oncolysis Through PKR InhibitionBig Data Offers Novel Insights for Oncolytic Virus ImmunotherapyUnderstanding and altering cell tropism of vesicular stomatitis virusMechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyHigh basal expression of interferon-stimulated genes in human bronchial epithelial (BEAS-2B) cells contributes to influenza A virus resistanceOncolytic immunotherapy: where are we clinically?Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsRIG-I is required for VSV-induced cytokine production by murine glia and acts in combination with DAI to initiate responses to HSV-1.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of MelanomaThe Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferonInduction of antiviral genes by the tumor microenvironment confers resistance to virotherapyOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.Oncolytic vaccinia virotherapy for endometrial cancerImmunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.Oncolytic Immunotherapy for Treatment of Cancer.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Vesiculovirus neutralization by natural IgM and complement.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitorsInterferon-Mediated Tumor Resistance to Oncolytic Virotherapy.Panorama from the oncolytic virotherapy summit.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats.Tumor Restrictions to Oncolytic Virus.The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
P2860
Q26739777-0270F569-8E0D-4998-A575-7ACEE56978E8Q26767209-41D44293-7F94-40C1-B0FD-B267E2E35B7CQ27687067-F711C49B-A933-4ED9-94D5-952B946B0215Q28083766-DF15FC41-1F7C-4B49-87C9-CC1E6613A607Q34337520-1555221E-3971-4D30-B798-5F46F807AB5EQ34405325-BDB373A6-B003-4D51-B908-C613600E36EAQ34656877-EF4EFF2B-0458-427E-95DC-6BEDF52FA129Q35641491-B90A8096-B059-48B6-BBD8-EAB41CE19A30Q35861186-59052F29-5916-4A93-A4E9-6DBE09E0A830Q35893563-4FCA73EC-2D7F-4FBA-9F18-690F17A97109Q36145522-3EE2BFEE-695B-4138-B294-B95F26296659Q36202610-42F485D6-1701-40AC-A401-82512EE530C4Q36257430-BA0B4119-9C27-4A32-AC63-C20EE808CC0AQ36682298-B9141F95-7D09-4AF5-963D-7BA3B9E23D44Q37076976-1AFAF843-96CD-4916-8057-41F24FACEB45Q37123143-5D0A0B7A-2865-452C-9626-8DAB4A6F7FFDQ37292354-53B7967B-AA91-4505-8B8D-B3C8C9160BFBQ37625385-9823E526-06D7-4868-A91C-E5F07CDF4630Q37641644-2026773B-8F0B-4471-9ECD-04D46A6E6FC1Q37646792-D74CB8A3-D123-4456-9B9A-70FC60D2CDC8Q37681801-C75BD557-23EF-40B9-A6AB-EE4304B7590AQ37688850-8581E32F-079B-46D4-AE3B-0638A9BBF153Q38221692-5120625B-FFD6-4F05-987D-DB3A410AA9E4Q38223419-F81DFBBC-6D9E-48B4-9867-F94A96EDD507Q38676507-E090B161-BDBE-4697-9A71-7458D0A9FBD7Q38793802-4B50371A-0CEB-4316-93B5-B8386C525CB1Q38848223-34FE50E9-37BF-439F-9F55-410D350737EDQ38860227-0DFB821A-A5B1-454B-8921-A27086B15772Q38955561-124EDE7D-D98F-4B55-AE4B-BC159522DE87Q39013686-4BA3A87E-F055-47F7-83BA-659F3761B71EQ39096636-5842D351-BAF7-4E00-BDCC-D109503C669CQ39109430-770632FC-884E-4D33-BACC-3166CE003866Q42934744-69EF1853-BB58-4C8B-8B9A-4DF9F15DB041Q45324769-23517E55-F7B0-4D41-8C1E-95FEF0BF5DE5Q47557500-8D96D4FA-2670-47B5-9DD1-73C91A0B6D0CQ47700338-E64812FC-FF77-42EC-ABAC-78FE1B0D9E76Q51846287-55C44EA5-D696-4737-9B8C-263D97AAAFAEQ52769266-2BA91F03-E7CD-46B0-87B7-B328A299C6BCQ54202657-BC737A4F-5CFF-4F31-A554-8D02DC7BA991Q57192791-EC09D0E7-E595-4A47-9F67-DA12F6E42464
P2860
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Resistance of pancreatic cance ...... f type I interferon signaling.
@en
Resistance of pancreatic cance ...... f type I interferon signaling.
@nl
type
label
Resistance of pancreatic cance ...... f type I interferon signaling.
@en
Resistance of pancreatic cance ...... f type I interferon signaling.
@nl
prefLabel
Resistance of pancreatic cance ...... f type I interferon signaling.
@en
Resistance of pancreatic cance ...... f type I interferon signaling.
@nl
P2093
P2860
P1433
P1476
Resistance of pancreatic cance ...... f type I interferon signaling.
@en
P2093
Andrea M Murphy
Eric Hastie
Megan Moerdyk-Schauwecker
Nirav R Shah
Pinku Mukherjee
Valery Z Grdzelishvili
P2860
P304
P356
10.1016/J.VIROL.2012.11.014
P407
P577
2012-12-14T00:00:00Z